Enanta Pharmaceuticals Inc. has patented compounds acting as nonstructural protein 3 (nsp3, PL-pro; SARS-CoV-2) inhibitors reported to be useful for the treatment of asthma, SARS-CoV-2 infection (COVID-19), rhinovirus, norovirus and lung infections.
The 2024 meeting of the International AIDS Society (IAS), which is being held in Munich this week, began with the announcement of another curative bone marrow transplant. The new case brings the total number of patients cured of HIV via a bone marrow transplant up to 7 since “Berlin patient” Timothy Ray Brown became the first such person in 2007.
Muscle fatigue associated with brain inflammation could be prevented by modulating certain cytokines. Researchers at Washington University in St. Louis (WUSTL) have studied inflammation in the CNS in infection models of Escherichia coli, SARS-CoV-2 and amyloid-β toxicity, unveiling its impact on motor function, the role of IL-6 in this process and how to mitigate it in chronic disease.
Zika virus (ZIKV), Dengue virus (DENV) and yellow fever virus (YFV) are closely related mosquito-borne flaviviruses for which effective treatment or prophylactic options are still scarce.
Previous preclinical studies of the prodrug of cidofovir, NPP-669, have shown its oral bioavailability, excellent metabolic and pharmacokinetic parameters, as well as its broad-range activity against dsDNA viruses in vitro.
Researchers from Children’s Hospital Boston and affiliated organizations have reported the discovery and preclinical characterization of a novel TLR7/8 agonist adjuvant for vaccination, PVP-037.
BK polyomavirus (BKV) reactivation in immunocompromised renal transplant patients may result in BKV-associated nephropathy and hemorrhagic cystitis. There are no suitable animal models of BKV to date, and although there are several treatment options under development, none have reached regulatory approval so far.
The industry is looking, with renewed hope, to the “promise” of messenger RNA (mRNA) therapeutics for a wide range of diseases beyond COVID-19, and not only in vaccine form but also for gene and cell therapies.
Scientists at Helmholtz Zentrum fur Infektionsforschung GmbH and Lead Discovery Center GmbH have identified α-hemolysin (Staphylococcus aureus) inhibitors reported to be useful for the treatment of staphylococcal pneumonia.
RSS
